The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Mr. Finney brings 35 years of leadership, operations and corporate development experienceSOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE ...

A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...

Novo Nordisk stock gains as its subcutaneous investigational candidate, amycretin, achieves superior weight loss compared to ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.

Novo Nordisk announces positive results from phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity: Bagsværd, Denmark Monday, January 27, 2025, 13:00 ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

"attachment_1199023" align="aligncenter" width="1456"] An elderly couple receiving insulin from a pharmacist, representing ...